Filing Flows › Interpace Biosciences (IDXG) › Q2 2026
Interpace Biosciences (IDXG) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Interpace Biosciences (IDXG) reported revenue of $9.1M for the second quarter 2026 (Q2 2026), -1% from a year earlier and +1% from the quarter before. Operating margin was 3.5%, net earnings $158K (1.7% of revenue).
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.1M | +1% | -1% |
| Gross profit | $5.7M | -4% | +7% |
| Operating profit | $321K | -71% | — |
| Net earnings | $158K | -78% | — |
| Operating cash flow | $98K | -65% | -81% |
| Free cash flow | $41K | -71% | — |
What changed
Revenue was $9.1M in Q2 2026, down 1% year over year and up 1% from the previous quarter.
Gross margin was 61.9%, up 4.8 points from Q2 2025. Operating profit was $321K, a 3.5% margin (up 8.6 points year over year). Operating expenses fell 7% while revenue fell 1%. The fastest-growing cost line was General & admin (+12%). Net earnings were $158K. The effective tax rate was 28.8%.
Operating cash flow was $98K (down 81% year over year), 62% of net earnings. Non-cash charges added back $127K of depreciation and amortization and $4K of share-based compensation. Working capital and other items used $191K. Capital expenditures of $57K left free cash flow of $41K.
Questions
What was Interpace Biosciences' revenue in the second quarter 2026?
Interpace Biosciences (IDXG) reported revenue of $9.1M for the second quarter 2026 (Q2 2026), -1% from a year earlier and +1% from the quarter before.
Was Interpace Biosciences profitable in the second quarter 2026?
Operating profit was $321K (3.5% of revenue) and net earnings $158K.